Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer
European committee backs Merck's Keytruda + Padcev combo for bladder cancer after Phase 3 trial slashes risk of recurrence by 47%.
Stocks · News reference
Moderna Stock More Than Doubled in a Month. Now Comes the Hard Part
Moderna stock has more than doubled after its cancer-vaccine breakthrough. Now investors face the harder question: Can it become an oncology powerhouse?
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
EU CHMP Adopts Positive Opinion Recommending Approval Of KEYTRUDA, Merck’s Anti-PD-1 Therapy, In Combination With Padcev As Neoadjuvant Treatment For Adults With Resectable Muscle-Invasive Bladder Cancer
Opinion granted based on positive results from the Phase 3 KEYNOTE-B15 trial, which demonstrated improvements in event-free survival, overall survival and pathologic complete response rateIf approved, KEYTRUDA plus
Moderna Stock Is Surging: What's Going On?
Moderna Inc. (NASDAQ: MRNA) shares are popping Thursday, extending a month-long rally that began with a Phase 3 cancer vaccine breakthrough.
Aethlon Medical, Oklo, CID HoldCo, Xenon Pharmaceuticals and Moderna: Why These 5 Stocks Are on Investors' Radars Today
Major U.S. indices closed higher on Thursday, with the Dow Jones Industrial Average rising 0.61% to 51,778.04
Nasdaq 100 Rallies as Oil Slides, Yields Retreat: Stock Market Today
Wall Street snapped a two-day losing streak Thursday as oil retreated from its geopolitical spike and the 10-year Treasury yield slipped back below 5%. Chipmakers led the rebound, with Intel, AMD and Micron all posting outsized gains, while gold climbed 2.5% to $4,369 an ounce. The bounce came one day after the Federal Reserve delivered its first interest rate hike since 2023 and signaled at least one more this year.